Barclays analyst Glen Santangelo lowered the firm’s price target on Idexx Laboratories (IDXX) to $800 from $850 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q4 repot, saying the fiscal 2026outlook “underwhelmed.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDXX:
- Idexx Laboratories price target lowered to $730 from $750 at UBS
- Balanced Risk Profile and Slower Near-Term Margin Expansion Support Neutral Stance on Idexx Laboratories
- Idexx Laboratories: Strong Q4 Execution, Robust 2026 Outlook, and Expanding Diagnostics Platform Support Buy Rating
- Idexx Laboratories price target lowered to $800 from $830 at BTIG
- Idexx Laboratories Earnings Call Highlights Resilient Growth